litlas
Log inCreate account

Jianying Zhou

Active 1996–2026

660
Papers
31,806
Citations
87
h-index
366
i10-index

Citations

Citations per year for Jianying Zhou1985: 1 citations1989: 1 citations1995: 1 citations1996: 4 citations1997: 32 citations1998: 20 citations1999: 38 citations2000: 50 citations2001: 53 citations2002: 70 citations2003: 91 citations2004: 100 citations2005: 179 citations2006: 102 citations2007: 144 citations2008: 172 citations2009: 177 citations2010: 174 citations2011: 187 citations2012: 171 citations2013: 234 citations2014: 329 citations2015: 393 citations2016: 514 citations2017: 568 citations2018: 597 citations2019: 952 citations2020: 1,776 citations2021: 1,817 citations2022: 1,606 citations2023: 1,291 citations2024: 1,876 citations2025: 1,184 citations2026: 138 citations2027: 1 citations1986–1988: no citations, so these years are not shown1990–1994: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorChina: 4,535 citing papers, 23.8% of this breakdownUnited States: 2,737 citing papers, 14.3% of this breakdownIndia: 902 citing papers, 4.7% of this breakdownUnited Kingdom: 866 citing papers, 4.5% of this breakdownAustralia: 689 citing papers, 3.6% of this breakdownItaly: 653 citing papers, 3.4% of this breakdownCanada: 562 citing papers, 3% of this breakdownSingapore: 562 citing papers, 3% of this breakdownGermany: 544 citing papers, 2.9% of this breakdownSpain: 538 citing papers, 2.8% of this breakdownSouth Korea: 499 citing papers, 2.6% of this breakdownFrance: 495 citing papers, 2.6% of this breakdown
0%23.8%Other 28.8%

Institutions

Fields

  • Computer Science45.3%
  • Medicine33%
  • Biochemistry, Genetics and Molecular Biology8%
  • Engineering7.6%
  • Immunology and Microbiology1.2%
  • Chemistry1.2%
  • Other3.7%

Topics

  • Cryptography and Data Security6.7%
  • Lung Cancer Treatments and Mutations4.1%
  • Lung Cancer Research Studies3.4%
  • Privacy-Preserving Technologies in Data3.1%
  • Blockchain Technology Applications and Security3%
  • Cancer Immunotherapy and Biomarkers2.9%
  • Other76.8%

Coauthors

All papers

Open in search
  1. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

    Authors: Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Олександр Войтко, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay Conev, J. Armstrong, Natalie Byrne, Norah J. Shire, Haiyi Jiang, Jonathan W. Goldman, Emilio Batagelj, Ignacio Casarini, Anea Viviana Pastor, S. Sena, Juan José Zarbá, Otto C. Burghuber, Sylvia Hartl, Maximilian J. Hochmair, Bernd Lamprecht, Michael Studnicka, Luís Alberto Schlittler, Fabrício Augusto Martinelli de Oliveira, Aknar Calabrich, Gustavo Girotto, Peo Dos Reis, Carlos Fausto Nino Gorini, Peo Rafael Martins De Marchi, Clarissa Baldotto, Cláudia Vaz de Melo Sette, Mauro Zukin, Nikolay Conev, Assen Dudov, Rumyana Ilieva, Krassimir Koynov, Rositsa Krasteva, Ivan Tonev, Spartak Valev, Violetka Venkova, Minghong Bi, Chengshui Chen, Yuan Chen, Zhendong Chen, Jian Fang, Jifeng Feng, Zhigang Han, Jie Hu, Yi Hu, Xing Li, Zongan Liang, Lin Zhong, Rui Ma, Shenglin Ma, Kejun Nan, Yongqian Shu, Kai Wang, Mengzhao Wang, Gang Wu, Nong Yang, Zhixiong Yang, Helong Zhang, Wei Zhang, Jun Zhao, Yanqiu Zhao, Caicun Zhou, Jianying Zhou, Xiangdong Zhou, Libor Havel, Vı́tězslav Kolek, Leona Koubková, Jaromı́r Roubec, Jana Skřičková, Milada Zemanová, C. Chouaïd, Werner Hilgers, H. Léna, Denis Moro‐Sibilot, G. Robinet, Pierre-Jean Souquet, Jürgen Alt, Helge Bischoff, Christian Grohé, Eckart Laack, Susanne Lang, Jens Panse, Niels Reinmuth, Christian Schulz and 146 more - The Lancet 2019 cited by 2,199

  2. On the features and challenges of security and privacy in distributed internet of things

    Authors: Rodrigo Roman, Jianying Zhou, Javier López - Computer Networks, Comput. Networks 2013 cited by 1,418

  3. Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer

    Authors: Hui Zhang, Tao Liu, Zhen Zhang, Samuel Payne, Bai Zhang, Jason McDermott, Jianying Zhou, Vladislav Petyuk, Li Chen, Debjit Ray, Shisheng Sun, Feng Yang, Lijun Chen, Jing Wang, Punit Shah, Seong Won, Paul Aiyetan, Sunghee Woo, Yuan Tian, Marina A. Gritsenko, Therese RW Clauss, Caitlin H. Choi, Matthew Monroe, Stefani N. Thomas, Song Nie, Chaochao Wu, Ronald Moore, Kun‐Hsing Yu, David L. Tabb, David Fenyö, Vineet Bafna, Yue Wang, Henry Rodriguez, Emily S. Boja, Tara Hiltke, Robert Rivers, Lori J. Sokoll, Heng Zhu, Ie‐Ming Shih, Leslie Cope, Akhilesh Pandey, Bing Zhang, M Snyder, Douglas A. Levine, Richard Smith, Daniel W. Chan, Karin Rodland, Steven A. Carr, Michael A. Gillette, Karl R. Klauser, Eric Kuhn, D.R. Mani, Philipp Mertins, Karen A. Ketchum, Ratna R. Thangudu, Shuang Cai, Mauricio Oberti, Amanda G. Paulovich, Jeffrey R. Whiteaker, Nathan Edwards, Peter B. McGarvey, Subha Madhavan, Pei Wang, Daniel W. Chan, Akhilesh Pandey, Ie‐Ming Shih, Hui Zhang, Zhen Zhang, Heng Zhu, Leslie Cope, Gordon A. Whiteley, Steven J. Skates, Forest M. White, Douglas A. Levine, Emily S. Boja, Christopher R. Kinsinger, Tara Hiltke, Mehdi Mesri, Robert Rivers, Henry Rodriguez, Kenna M. Shaw, Stephen E. Stein, David Fenyö, Tao Liu, Jason McDermott, Samuel Payne, Karin Rodland, Richard Smith, Paul A. Rudnick, M Snyder, Yingming Zhao, Xian Chen, David F. Ransohoff, Andrew N. Hoofnagle, D.C. Liebler, Melinda E. Sanders, Zhiao Shi, Robbert J.C. Slebos, David L. Tabb, Bing Zhang and 10 more - Cell 2016 cited by 1,126

  4. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

    Authors: Caicun Zhou, Gongyan Chen, Yunchao Huang, Jianying Zhou, Lizhu Lin, Jifeng Feng, Zhehai Wang, Yongqian Shu, Jianhua Shi, Yi Hu, Qiming Wang, Ying Cheng, Fengying Wu, Jianhua Chen, Xiaoyan Lin, Yongsheng Wang, Jianan Huang, Jiuwei Cui, Lejie Cao, Yunpeng Liu, Yiping Zhang, Yueyin Pan, Jun Zhao, Liping Wang, Jianhua Chang, Qun Chen, Xiubao Ren, Wei Zhang, Yun Fan, Zhiyong He, Jian Fang, Kangsheng Gu, Xiaorong Dong, Tao Zhang, Wei Shi, Jianjun Zou - The Lancet Respiratory Medicine 2020 cited by 505

  5. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer

    Authors: Jie Wang, Shun Lü, Xinmin Yu, Yanping Hu, Yuping Sun, Zhijie Wang, Jun Zhao, Yan Yu, Chunhong Hu, Kunyu Yang, Guosheng Feng, Kejing Ying, Wu Zhuang, Jianying Zhou, Jingxun Wu, Shiang Jiin Leaw, Jing Zhang, Xiao Lin, Liang Liang, Nong Yang - JAMA Oncology 2021 cited by 398

  6. AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

    Authors: Shun Lü, Xiaorong Dong, Hong Jian, Jianhua Chen, Gongyan Chen, Yuping Sun, Yinghua Ji, Ziping Wang, Jianhua Shi, Junguo Lu, Shaoshui Chen, Dongqing Lv, Guojun Zhang, Chunling Liu, Juan Li, Xinmin Yu, Zhong Lin, Zhuang Yu, Zhehai Wang, Jiuwei Cui, Xingxiang Xu, Jian Fang, Jifeng Feng, Zhixiang Xu, Rui Ma, Jie Hu, Nong Yang, Xiangdong Zhou, Xiaohong Wu, Chengping Hu, Zhihong Zhang, You Lü, Yanping Hu, Liyan Jiang, Qiming Wang, Renhua Guo, Jianying Zhou, Baolan Li, Chunhong Hu, Wan-cheng Tong, Helong Zhang, Lin Ma, Yuan Chen, Zhijun Jie, Yu Yao, Longzhen Zhang, Weng Jie, Weidong Li, Jianping Xiong, Xianwei Ye, Jianchun Duan, Haihua Yang, Meili Sun, Changan Sun, Hongying Wei, Chuan Li, Siraj M. Ali, Vincent A. Miller, Qiong Wu - Journal of Clinical Oncology 2022 cited by 279

  7. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

    Authors: Caicun Zhou, Benjamin Solomon, Herbert H. Loong, Keunchil Park, M. Pérol, Edurne Arriola, Silvia Novello, Baohui Han, Jianying Zhou, Andrea Ardizzoni, M. Perez Mak, Fernando C. Santini, Yasir Y. Elamin, Alexander Drilon, Jürgen Wolf, Nalin Payakachat, Minji K. Uh, Deborah Rajakumar, Hongmei Han, Tarun Puri, Victoria Soldatenkova, Aimee Bence Lin, Boris K. Lin, Kōichi Goto - New England Journal of Medicine 2023 cited by 213

  8. Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

    Authors: Caicun Zhou, Caicun Zhou, Lin Wu, Yun Fan, Zhehai Wang, Lianke Liu, Gongyan Chen, Li Zhang, Dingzhi Huang, Shundong Cang, Zhixiong Yang, Jianying Zhou, Chengzhi Zhou, Chengzhi Zhou, Baolan Li, Juan Li, Min Fan, Jiuwei Cui, Yuping Li, Hui Zhao, Jian Fang, Jianxin Xue, Chengping Hu, Ping Sun, Yingying Du, Hui Zhou, Shuyan Wang, Wen Zhang - Journal of Thoracic Oncology 2021 cited by 317

  9. Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

    Authors: Yunpeng Yang, Zhehai Wang, Jian Fang, Qitao Yu, Baohui Han, Shundong Cang, Gongyan Chen, Xiaodong Mei, Zhixiong Yang, Rui Ma, Minghong Bi, Xiubao Ren, Jianying Zhou, Baolan Li, Yong Song, Jifeng Feng, Juan Li, Zhiyong He, Rui Zhou, Weimin Li, You Lü, Yingyi Wang, Lijun Wang, Nong Yang, Yan Zhang, Zhuang Yu, Yanqiu Zhao, Conghua Xie, Ying Cheng, Hui Zhou, Shuyan Wang, Donglei Zhu, Wen Zhang, Li Zhang - Journal of Thoracic Oncology 2020 cited by 396

  10. Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

    Authors: Shun Lü, Jie Wang, Yan Yu, Xinmin Yu, Yanping Hu, Xinghao Ai, Zhiyong Ma, Xingya Li, Wu Zhuang, Yunpeng Liu, Weidong Li, Jiuwei Cui, Dong Wang, Wangjun Liao, Jianying Zhou, Zhehai Wang, Yuping Sun, Xiusong Qiu, Jie Gao, Yuanyuan Bao, Liang Liang, Mengzhao Wang - Journal of Thoracic Oncology 2021 cited by 278

  11. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

    Authors: James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee, Yun Fan, Filippo de Marinis, Eiji Iwama, Takako Inoue, Jerónimo Rafael Rodríguez‐Cid, Li Zhang, Cheng‐Ta Yang, Emmanuel de la Mora Jimenez, Jianying Zhou, M. Pérol, Ki Hyeong Lee, David Vicente, Eiki Ichihara, Gregory J. Riely, Yiwen Luo, Diana Chirovsky, M. Catherine Pietanza, Niyati Bhagwati, Shun Lü, Michael Boyer, Rina Hui, Mark E. Wong, Andrew Mant, Phillip Parente, Thomas John, Sagun Parakh, Gilberto de Castro, Gustavo Werutsky, Sérgio Jobim Azevedo, Fábio Franke, Joilda Batista De Almeida Rego, Pedro Rafael Martins De Marchi, Gustavo Dix Junqueira, Fernanda Maris Peria, Leandro Brust, Parneet Cheema, Mark Doherty, Ambika Parmar, Ines B. Menjak, Natasha B. Leighl, Jason Agulnik, Shun Lü, Zhigang Han, Jiuwei Cui, Li Zhang, Ying Cheng, Gongyan Chen, Helong Zhang, Yu Yao, Chengping Hu, Qiming Wang, Xin Zhang, Yong Zhang, Jianying Zhou, Kejing Ying, Yun Fan, Yan Wang, Ziping Wang, Ji‐Feng Feng, Yingying Du, Lin Wu, Cheng Zhi Huang, Xiangdong Zhou, M. Pérol, Julien Dômont, Corinne Lamour, Julien Dutilh, Youssef Oulkhouir, Virginie Westeel, D. Carmier, Bruno Coudert, Aurélie Lagrange, Dominique Spaëth, Stanislas Ropert, Daniel C. Christoph, Jens Kern, Hans‐Georg Kopp, Frank Griesinger, Rainer Wiewrodt, Martin Wermke, Claas Wesseler, Annette Mueller, G Vogel, Victor Lee, Chung Man James Ho, Siu Hong Oscar Chan, Sing Hung Lo, Shi Feng Jonathan Nyaw, Yu Chung Jacky Li, Jair Bar, Maya Gottfried, Julia Dudnik, Alona Zer, Mor Moskovitz, Mirjana Wollner, Ofer Rotem, Sivan Shamai and 111 more - Journal of Clinical Oncology 2024 cited by 142

  12. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

    Authors: Yi‐Long Wu, Ying Cheng, Jianying Zhou, Shun Lü, Yiping Zhang, Jun Zhao, Dong‐Wan Kim, Ross A. Soo, Sang‐We Kim, Hongming Pan, Yuh‐Min Chen, Chih‐Feng Chian, Xiaoqing Liu, Daniel S.W. Tan, Rolf Bruns, Josef Straub, Andreas Johne, J. Scheele, Keunchil Park, James Chih‐Hsin Yang, Yi‐Long Wu, Xiaoqing Liu, Zhe Liu, Shun Lu, Xi Chen, Hongming Pan, Mengzhao Wang, YU Shi-ying, Helong Zhang, Yiping Zhang, Jian Fang, Wei Li, Jianying Zhou, Jun Zhao, Ying Cheng, Chih-Hsin Yang, Gee‐Chen Chang, Yuh‐Min Chen, Te‐Chun Hsia, Chih‐Feng Chian, Cheng-Ta Yang, Chin‐Chou Wang, Sang‐We Kim, Keunchil Park, Dong‐Wan Kim, Byoung Chul Cho, Ki Hyeong Lee, Young‐Chul Kim, Ho Jung An, In Sook Woo, Y. Choi, Sang Won Shin, Jong Seok Lee, Joo-Hang Kim, Seung Soo Yoo, Terufumi Kato, Naofumi Shinagawa, Ross A. Soo, Shao Weng Daniel Tan, Lynette Si-Mien Ngo, Kananathan Ratnavelu, Azura Rozila Ahmad, Chong Kin Liam, Filippo de Marinis, Pierfrancesco Tassone, Amelia Insa Molla, Antonio Calles, Martín Emilio Lázaro Quintela, Enriqueta Felip Font, Anne‐Marie C. Dingemans, Lynne A. Bui - The Lancet Respiratory Medicine 2020 cited by 258

  13. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study

    Authors: Qing Zhou, Chong‐Rui Xu, Ying Cheng, Yunpeng Liu, Gongyan Chen, Jiuwei Cui, Nong Yang, Yong Song, Xiaoling Li, Shun Lü, Jianying Zhou, Zhiyong Ma, Shiying Yu, Cheng Huang, Yongqian Shu, Zhen Wang, Jin‐Ji Yang, Hai‐Yan Tu, Wen‐Zhao Zhong, Yi‐Long Wu - Cancer Cell 2021 cited by 228

  14. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study

    Authors: Shun Lü, Jian Fang, Xingya Li, Lejie Cao, Jianying Zhou, Qisen Guo, Zongan Liang, Ying Cheng, Liyan Jiang, Nong Yang, Zhigang Han, Jianhua Shi, Yuan Chen, Hua Xu, Helong Zhang, Gongyan Chen, Rui Ma, Sanyuan Sun, Yun Fan, Jing Li, Xian Luo, Linfang Wang, Yongxin Ren, Weiguo Su - The Lancet Respiratory Medicine 2021 cited by 204

  15. Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR -mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.

    Authors: James Chih‐Hsin Yang, Dae Ho Lee, Jong Seok Lee, Yun Fan, Filippo de Marinis, Isamu Okamoto, Takako Inoue, Jerónimo Rafael Rodríguez Cid, Zhang Li, Cheng‐Ta Yang, Emmanuel de la Mora Jimenez, Jianying Zhou, M. Pérol, Ki Hyeong Lee, David Vicente, Eiki Ichihara, Gregory J. Riely, Yiwen Luo, Niyati Bhagwati, Shun Lü - Journal of Clinical Oncology 2023 cited by 94

  16. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

    Authors: Yi‐Long Wu, Shun Lü, Ying Cheng, Caicun Zhou, Jie Wang, Tony Mok, Li Zhang, Hai-Yan Tu, Lin Wu, Jifeng Feng, Yiping Zhang, Alexander Luft, Jianying Zhou, Zhiyong Ma, You Lü, Chengping Hu, Yuankai Shi, Christine Baudelet, Junliang Cai, Jianhua Chang - Journal of Thoracic Oncology 2019 cited by 358

  17. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

    Authors: Johan Maertens, Galia Rahav, Dong‐Gun Lee, Alfredo Ponce‐de‐León, Isabel Cristina Ramírez Sánchez, Н Н Климко, Anne Sonet, Shariq Haider, Juan D. Vélez, Issam Raad, Liang‐Piu Koh, Meinolf Karthaus, Jianying Zhou, Ronen Ben‐Ami, Mary Motyl, Seongah Han, Anjana Grandhi, Hetty Waskin - The Lancet 2021 cited by 276

  18. A Systematic Survey of Attack Detection and Prevention in Connected and Autonomous Vehicles

    Authors: Trupil Limbasiya, Ko Zheng Teng, Sudipta Chattopadhyay, Jianying Zhou - Vehicular Communications, Veh. Commun. 2022 cited by 71

  19. Policy-based Chameleon Hash for Blockchain Rewriting with Black-box Accountability

    Authors: Yangguang Tian, Nan Li, Yingjiu Li, Pawel Szalachowski, Jianying Zhou - Annual Computer Security Applications Conference, ACSAC 2020 cited by 70

  20. D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results

    Authors: Ziming Li, Zhengbo Song, Yanqiu Zhao, Pingli Wang, Liyan Jiang, Yi Gong, Jianying Zhou, Hong Jian, Xiaorong Dong, Zhuang Wu, Shundong Cang, Nong Yang, Jian Fang, Jianhua Shi, Jun‐Guo Lu, Rui Ma, Ping Wu, Yingqian Zhang, Mengmeng Song, Chunwei Xu, Zhe Shi, Ling Zhang, Yaolin Wang, Xicheng Wang, Yiping Zhang, Shun Lü - Journal of Thoracic Oncology 2023 cited by 81

  21. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study

    Authors: Shufa Zheng, Jian‐Gao Fan, Fei Yu, Baihuan Feng, Bin Lou, Qianda Zou, Guoliang Xie, Sha Lin, Ruonan Wang, Xianzhi Yang, Weizhen Chen, Qi Wang, Dan Zhang, Yanchao Liu, Renjie Gong, Zhaohui Ma, Siming Lu, Yanyan Xiao, Yaxi Gu, Jinming Zhang, Hangping Yao, Kaijin Xu, Xiaoyang Lu, Guoqing Wei, Jianying Zhou, Qiang Fang, Hongliu Cai, Yunqing Qiu, Jifang Sheng, Yu Chen, Tingbo Liang - BMJ 2020 cited by 1,592

  22. Surveying the Development of Biometric User Authentication on Mobile Phones

    Authors: Weizhi Meng, Duncan S. Wong, Steven Furnell, Jianying Zhou - IEEE Communications Surveys & Tutorials, IEEE Commun. Surv. Tutorials 2014 cited by 297

  23. On the Security of Containers: Threat Modeling, Attack Analysis, and Mitigation Strategies

    Authors: Ann Yi Wong, Eyasu Getahun Chekole, Martín Ochoa, Jianying Zhou - Computers & Security, Comput. Secur. 2023 cited by 49

  24. Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

    Authors: Mengzhao Wang, James Chih-Hsin Yang, Paul L. Mitchell, Jian Fang, D. Ross Camidge, Weiqi Nian, Chao-Hua Chiu, Jianying Zhou, Yanqiu Zhao, Wu-Chou Su, Tsung-Ying Yang, Viola W. Zhu, Michael Millward, Yun Fan, Wen-Tsung Huang, Ying Cheng, Liyan Jiang, Daniel Brungs, Lyudmila Bazhenova, Chee Khoon Lee, Bo Gao, Yan Xu, Wei-Hsun Hsu, Li Zheng, Pasi A. Jänne - Cancer Discovery 2022 cited by 119